Ovarian Cancer | Bradley J Monk, MD

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent one-on-one interview with Dr Monk featuring emerging research and cases from his practice: Guidelines for germline and somatic BRCA testing in ovarian cancer (00:00) Incidence and potential impact of other clinically relevant genetic abnormalities on clinical decision-making in the front-line setting (2:52) Patient selection for neoadjuvant systemic therapy in clinical practice (5:31) Bevacizumab as a component of neoadjuvant systemic therapy for patients with ovarian cancer (7:52) Clinical approach to patient selection for neoadjuvant chemotherapy; perspective on optimal schedule and dose of neoadjuvant regimen (10:47) Importance of the extent of response to neoadjuvant chemotherapy in the timing of debulking surgery (13:57) Therapeutic approach for patients with newly diagnosed ovarian cancer, germline BRCA mutations, bilateral pleural effusions and liver metastases (16:17) Lingering controversies regarding the use of intraperitoneal chemotherapy for ovarian cancer (18:30) GOG-0252: Design and results of a Phase III trial of intravenous or intraperitoneal chemotherapy, each in combination with bevacizumab, for advanced ovarian cancer (20:40) Perspective on the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for Stage III or IV epithelial ovarian cancer after initial surgical resection (22:29) Importance of disease stage and amount of residual disease in the decision to use bevacizumab as a component of primary therapy after debulking surgery (25:21) Evaluating the optimal duration of maintenance bevacizumab (26:39) Effect of bevacizumab on progression-free survival for patients with high-risk disease (28:19) Risk of bevacizumab-associated gastrointestinal perforation; contraindications to bevacizumab (29:57) Perspective on combining a PARP inhibitor with bevacizumab as maintenance therapy for patients with advanced platinum-sensitive ovarian cancer (32:15) PAOLA-1: An ongoing Phase III trial of olaparib combined with bevacizumab as maintenance therapy for patients with advanced ovarian cancer after first-line platinum-based chemotherapy in combination with bevacizumab (35:42) Practical approaches to mitigating carboplatin/paclitaxel-induced peripheral neuropathy (36:58) Comparison of treatment-associated neurotoxicity with nab paclitaxel and solvent-based paclitaxel (39:36) Clinical experience with bevacizumab for ovarian cancer; management of hypertension and proteinuria (41:08) Activity and ongoing investigation of anti-angiogenic agents alone or in combination with PARP inhibitors for advanced ovarian cancer (42:46) FDA breakthrough therapy designation for lenvatinib in combination with pembrolizumab for previously treated advanced microsatellite instability (MSI)-nonhigh/mismatch repair proficient endometrial cancer (44:14) Rationale for the design of ongoing studies combining immune checkpoint inhibitors with anti-angiogenic agents and/or PARP inhibitors (45:47) Modulation of gut microbiome to enhance response to anti-PD-1 immunotherapy; impact of antibiotics on response to treatment with immune checkpoint inhibitors (49:00) Select publications